Search | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Azacitidine

    ... turned off, MDS cells and cancer cells can grow freely. Azacitidine is approved by the U.S. Food and Drug Administration (FDA) for ...

    Drug last updated 03/24/2016 - 12:32pm.

  2. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United ... of MDS or acute myeloid leukemia (AML) and, in the case of azacitidine, prolong survival in higher-risk patients. Neither is curative, ...

    Research Article last updated 10/23/2017 - 11:00am.

  3. Clinical trial reveals genetic fault that reduces the effectiveness of leukemia treatment

    ... to the current standard treatment, a drug called azacitidine . Although no additional benefit was seen by the new ... by older patients for whom the recently developed drug azacitidine, which can be delivered as an out-patient, represents an important ...

    Research Article last updated 09/29/2017 - 10:32am.

  4. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United ... of MDS or acute myeloid leukemia (AML) and, in the case of azacitidine, prolong survival in higher-risk patients. Neither is curative, ...

    Research Article last updated 10/02/2017 - 10:03am.

  5. Foundation Update - April 2016

    ... erythropoietin (Procrit®), G-CSF, (Neupogen®), azacitidine , (Vidaza®) and deferoxamine (Desferal®). My hemoglobin ... far this year which is more than usual for me, and my last azacitidine (Vidaza®) treatment in June didn't seem to have much benefit. ...

    Article last updated 10/09/2017 - 2:57pm.

  6. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117

    ... 9, 2017 Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce ...

    Research Article last updated 05/22/2017 - 10:52am.

  7. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

    ... and quality of life and, in the case of azacitidine , prolonged survival in a large randomized trial. However, ... Furthermore, the 24-month median survival observed with azacitidine in the landmark AZA-001 trial has not been replicated in population-based studies or in other clinical trials using azacitidine monotherapy arms. Herein, we critically review the accumulating ...

    Research Article last updated 09/11/2017 - 9:04am.

  8. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes

    ...

    Research Article last updated 08/03/2017 - 9:16am.

  9. Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes

    ...

    Research Article last updated 08/03/2017 - 9:15am.

  10. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... (2006-2012) to estimate the impact of DMT-initiation ( azacitidine , decitabine , or lenalidomide ) timing (≤ 3 ...

    Research Article last updated 09/13/2017 - 8:58am.